Does GILTERITINIB Cause Differentiation syndrome? 80 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 80 reports of Differentiation syndrome have been filed in association with GILTERITINIB (Xospata). This represents 2.2% of all adverse event reports for GILTERITINIB.
80
Reports of Differentiation syndrome with GILTERITINIB
2.2%
of all GILTERITINIB reports
24
Deaths
38
Hospitalizations
How Dangerous Is Differentiation syndrome From GILTERITINIB?
Of the 80 reports, 24 (30.0%) resulted in death, 38 (47.5%) required hospitalization, and 8 (10.0%) were considered life-threatening.
Is Differentiation syndrome Listed in the Official Label?
Yes, Differentiation syndrome is listed as a known adverse reaction in the official FDA drug label for GILTERITINIB.
What Other Side Effects Does GILTERITINIB Cause?
Acute myeloid leukaemia (366)
Febrile neutropenia (346)
Off label use (334)
Platelet count decreased (327)
Pneumonia (302)
Myelosuppression (300)
Pyrexia (281)
Death (206)
Product use issue (189)
Hepatic function abnormal (181)
What Other Drugs Cause Differentiation syndrome?
TRETINOIN (251)
ARSENIC TRIOXIDE (180)
ENASIDENIB (102)
IVOSIDENIB (80)
AZACITIDINE (50)
HYDROXYUREA (41)
DEXAMETHASONE (38)
CYTARABINE (33)
PREDNISONE (25)
PIPERACILLIN\TAZOBACTAM (24)
Which GILTERITINIB Alternatives Have Lower Differentiation syndrome Risk?
GILTERITINIB vs GIMERACIL\OTERACIL\TEGAFUR
GILTERITINIB vs GINKGO
GILTERITINIB vs GIVINOSTAT
GILTERITINIB vs GIVOSIRAN
GILTERITINIB vs GLASDEGIB